Table 1.

Crude patterns of prescriptions for each antidiabetic medication by case and control status

Antidiabetic medicationaCasesControls
nb = 393# of prescriptionsc (16,366)Range of prescriptionsd (1–552)Years of use per persone (0.02–15.4)nb = 3,930# of prescriptionsc (173,358)Range of prescriptionsd (1–552)Years of use per persone (0.01–19.2)
No prescriptions for at least 1 y78n/an/an/a798n/an/an/a
Insulin
 Fast acting301,0321–5520.98–15.445212,8241–5520.04–18.6
 Intermediate acting1122,7701–2240.03–14.31,31530,6371–5300.02–19.2
 Intermediate, rapid onset821,9961–980.05–12.885721,3821–3880.01–16.2
 Other analogues, long acting3193–100.48–3.21239441–440.14–4.0
Metforminf1463,9165–2100.05–11.41,59638,9781–2690.02–16.8
Sulfonamides2275,0001–1730.02–14.122652,0842–3560.02–16.2
Combination3151–80.28–0.51383392–610.09–3.11
α-Glucoside inhibitors193011–1060.05–7.51852,3831–1630.01–10.9
Thiazolidinedine2172–150.02–1.5313951–570.03–7.7
Dipeptidyl peptidase 4 inhibitors2123–180.27–0.53381991–360.04–1.4
Other5631–380.19–2.5761,1341–1130.02–6.8
  • aPrescriptions for each antidiabetic medication regardless of duration of use.

  • bNumber of case and control subjects receiving any prescription for each antidiabetic medication. Cases and controls can use multiple types of medication.

  • cTotal number of prescriptions for each antidiabetic medication does not take into account prescription product amount or unit size.

  • dRange of number of prescriptions per person does not take into account prescription product amount or unit size.

  • eRange of number of years prescribed per person regardless of duration of use.

  • fNumber of case and control subjects include women with less than 1 year duration of metformin use.